Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 343 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
Interventions
Surovatamig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 18 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
14
States / cities
La Jolla, California • Denver, Colorado • New Haven, Connecticut + 11 more
Completed No phase listed Observational Accepts healthy volunteers

A Safety Study Assessing the Effects of Receiving Genome Sequencing Results

NCT01692223
Conditions
History of Cancer
Interventions
qualitative interviews
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Cancer
Interventions
EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC), Interleukin-2, Interferon-alpha
Biological · Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Springfield, Illinois • Lansing, Michigan • Houston, Texas
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide
Drug
Lead sponsor
Shire
Industry
Eligibility
16 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
40
States / cities
Little Rock, Arkansas • Bell Gardens, California • Granada Hills, California + 35 more
Conditions
Stroke
Interventions
myomo e100
Device
Lead sponsor
Myomo
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charlestown, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Efficacy and Safety of COVID-19 Vaccine in Cancer Patients

NCT04865133
Conditions
COVID-19 Infection, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Falls with Injuries
Interventions
Observation
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Kidney Disease
Interventions
darTreg infusion
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Conditions
Hemophilia B with Inhibitor, Hemophilia B
Interventions
SerpinPC
Drug
Lead sponsor
ApcinteX Ltd
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Tampa, Florida • Greenville, North Carolina
Enrolling by invitation No phase listed Observational

Long Term Follow-up for RGX-202

NCT06491927
Conditions
Duchenne Muscular Dystrophy
Interventions
No Intervention
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 2 more
Conditions
Spinal Cord Injuries or Similar Neurological Weakness
Interventions
Ekso exoskeleton
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Completed No phase listed Observational Accepts healthy volunteers

Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine

NCT04600388
Conditions
Menstrual Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Poughkeepsie, New York
Conditions
Malaria
Interventions
PfSPZ Vaccine
Biological
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Conditions
Gall Bladder Disease, Bile Duct Diseases, Acute Cholecystitis, Kidney, Liver, Appendix, Spleen Disease, Prostate
Interventions
laparoscopic procedure
Device
Lead sponsor
Teleflex
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • New Hyde Park, New York • Wilmington, North Carolina
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Standard of Care
Biological · Other
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
45
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 39 more
Conditions
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept
Genetic · Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
25 Years to 89 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
Durvalumab, Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more
Conditions
Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 18 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 1 more
Conditions
AML, ALL, MDS
Interventions
Observational
Other
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
2
States / cities
Duarte, California • New York, New York
Conditions
Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, Hemophilia A, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, Hematologic Diseases, Hemorrhagic Disorders, Factor VIII Deficiency
Interventions
Standard of Care FVIII Replacement therapy
Drug
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Timeline
2019 – 2023
U.S. locations
6
States / cities
San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 3 more
Conditions
Neuralgia, Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions
Magnetic Peripheral Nerve Stimulation
Device
Lead sponsor
NeuraLace Medical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Enrolling by invitation No phase listed Observational

INDUCE: A Prospective 2-Year Spine Registry

NCT06971835
Conditions
Subjects Treated With NMP as Part of Their Spine Surgery, Degenerative Disc Disease (DDD)
Interventions
NMP
Device
Lead sponsor
Red Rock Regeneration Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Shreveport, Louisiana • Salt Lake City, Utah
Conditions
Hematuria, Dysuria, Bladder Cancer
Interventions
Not listed
Lead sponsor
Medical Diagnostic Laboratories, LLC
Industry
Eligibility
25 Years and older
Enrollment
1,115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Staten Island, New York
Conditions
Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
Interventions
Relugolix-Containing Product
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
0 Years and older · Female only
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Wilmington, North Carolina